BioSpace News Archive

NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on January 10, 2024.

NanoImaging Services, the leading provider of cryo-electron microscopy services to the pharmaceutical and biotechnology communities, announced the appointment of John Rigg as Chief Executive Officer.

Tibidabo Scientific Industries Ltd (“Tibidabo Scientific”) is delighted to announce the appointment of Paul McEvoy as Group Chief Commercial Officer.

Cartesian Therapeutics, Inc. announced positive twelve-month follow-up data from its Phase 2a trial of Descartes-08 in patients with generalized myasthenia gravis, a chronic autoimmune disorder that causes disabling muscle weakness and fatigue.

Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, provided a business update and outlined its strategic outlook and expected milestones for 2024.

NeuroPace, Inc. announced preliminary unaudited revenue for the quarter and year ended December 31, 2023 and provided business updates.

OKYO Pharma Limited reports positive safety and efficacy results in its Phase 2, randomized, double-masked, placebo-controlled trial evaluating the safety and efficacy of OK-101 ophthalmic solution in subjects with DED.

Mereo BioPharma Group plc, a clinical-stage biopharmaceutical company focused on rare diseases, provided an update on its pipeline programs as well as an update on recent corporate developments.

Boston Scientific Corporation announced it has entered into a definitive agreement to acquire Axonics, Inc., a publicly traded medical technology company primarily focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction.

f, which is building the leading platform for cell programming and biosecurity, announced the formation of its new Biopharma Advisory Board.